Dutch Mail-Order Pharmacy Plan Row

28 July 1996

In the Netherlands, a number of pharmacies have refused to renew their contracts with health insurer Zilveren Kruis, in protest against the insurer's intention to establish a mail-order pharmacy business as a way of cutting costs. This service will be aimed primarily at chronically-ill patients.

Pharmacists now receive a 10-guilder ($6.00) fee for each prescription dispensed, and they want this increased for prescriptions that are not in future to be filled through mail order.

The pharmacists' national association, the KNMP, says there is "insufficient support" among its members for a national agreement with Zilveren Kruis, and it suggests that its members seek agreements with the insurer on a regional basis. In areas where no agreement exists, Zilveren Kruis policyholders will have to pay for their medicines in cash and then seek reimbursement from the insurer.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight